What is HC Wainwright's Estimate for IONS Q1 Earnings?

Key Points

• HC Wainwright projects Q1 2027 EPS of ($0.62) for Ionis and maintains a "Buy" rating with a $125 price target.
• Ionis reported Q1 EPS of ($0.56), beating the consensus of ($0.85), and posted revenue of $246 million, up 86.4% year-over-year and above analyst expectations.
• The stock carries a consensus rating of "Moderate Buy" (majority Buy ratings) with a consensus price target of $99.35, and a market cap around $12.4 billion while trading near $75.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for Ionis Pharmaceuticals in a report released on Thursday, April 30th. HC Wainwright analyst M. Kapoor anticipates that the company will post earnings per share of ($0.62) for the quarter. HC Wainwright currently has a "Buy" rating and a $125.00 price target on the stock. The consensus estimate for Ionis Pharmaceuticals' current full-year earnings is ($4.07) per share.

Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last issued its quarterly earnings results on Wednesday, April 29th. The company reported ($0.56) EPS for the quarter, topping analysts' consensus estimates of ($0.85) by $0.29. Ionis Pharmaceuticals had a negative return on equity of 58.65% and a negative net margin of 30.91%.The company had revenue of $246.00 million for the quarter, compared to analysts' expectations of $195.57 million. During the same quarter last year, the business earned ($0.93) earnings per share. Ionis Pharmaceuticals's revenue was up 86.4% on a year-over-year basis.

IONS has been the topic of a number of other research reports. Canaccord Genuity Group started coverage on Ionis Pharmaceuticals in a research report on Monday, April 20th. They issued a "buy" rating and a $110.00 target price on the stock. Morgan Stanley lifted their target price on Ionis Pharmaceuticals from $95.00 to $130.00 and gave the company an "overweight" rating in a research report on Tuesday, April 21st. Oppenheimer reiterated an "outperform" rating and issued a $111.00 target price on shares of Ionis Pharmaceuticals in a research report on Thursday. Barclays lifted their target price on Ionis Pharmaceuticals from $106.00 to $115.00 and gave the company an "overweight" rating in a research report on Thursday. Finally, Needham & Company LLC lifted their target price on Ionis Pharmaceuticals from $103.00 to $105.00 and gave the company a "buy" rating in a research report on Wednesday, March 25th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $99.35.

Ionis Pharmaceuticals Price Performance

Shares of NASDAQ IONS opened at $75.28 on Monday. The company has a debt-to-equity ratio of 2.75, a quick ratio of 4.09 and a current ratio of 4.10. Ionis Pharmaceuticals has a 52 week low of $31.66 and a 52 week high of $86.74. The stock has a market capitalization of $12.44 billion, a P/E ratio of -36.37 and a beta of 0.38. The stock's fifty day moving average is $75.30 and its 200 day moving average is $77.35.

Insider Transactions at Ionis Pharmaceuticals

In other Ionis Pharmaceuticals news, EVP Kyle Jenne sold 37,277 shares of Ionis Pharmaceuticals stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $75.85, for a total value of $2,827,460.45. Following the transaction, the executive vice president owned 11,714 shares in the company, valued at $888,506.90. The trade was a 76.09% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Elizabeth L. Hougen sold 215,048 shares of Ionis Pharmaceuticals stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $72.40, for a total value of $15,569,475.20. Following the sale, the executive vice president directly owned 92,832 shares in the company, valued at $6,721,036.80. The trade was a 69.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 666,443 shares of company stock valued at $50,623,742. Company insiders own 2.71% of the company's stock.

Institutional Trading of Ionis Pharmaceuticals

A number of hedge funds have recently made changes to their positions in IONS. Goldman Sachs Group Inc. boosted its stake in shares of Ionis Pharmaceuticals by 72.5% during the first quarter. Goldman Sachs Group Inc. now owns 652,518 shares of the company's stock valued at $19,686,000 after purchasing an additional 274,310 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Ionis Pharmaceuticals by 6.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 659,435 shares of the company's stock valued at $19,895,000 after purchasing an additional 39,794 shares in the last quarter. Focus Partners Wealth boosted its stake in shares of Ionis Pharmaceuticals by 30.1% during the first quarter. Focus Partners Wealth now owns 9,832 shares of the company's stock valued at $297,000 after purchasing an additional 2,277 shares in the last quarter. Franklin Resources Inc. acquired a new stake in shares of Ionis Pharmaceuticals during the second quarter valued at about $220,000. Finally, Prudential Financial Inc. boosted its stake in shares of Ionis Pharmaceuticals by 47.8% during the second quarter. Prudential Financial Inc. now owns 9,254 shares of the company's stock valued at $341,000 after purchasing an additional 2,991 shares in the last quarter. 93.86% of the stock is owned by institutional investors and hedge funds.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company's proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis' pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.